Vascular reperfusion in pulmonary thromboembolism: certainties and uncertainties

Amado, Andreia

doi:10.1590/s1806-37562018000030004

Cited by 1 publication

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…VTE is the third most common cause of cardiovascular death, following acute coronary artery disease and stroke, and is responsible for more than 3 million deaths/year worldwide. 1,2 Since the 1960s, it has been known that anticoagulation favorably impacts the outcome of VTE, 3,4 and it is well established that this is the basic step in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), 5 the two most common VTE clinical presentations. However, even when adequately treated, VTE mortality is surprisingly high.…”

Section: Introductionmentioning

confidence: 99%

Extended anticoagulation after venous thromboembolism: should it be done?

Fernandes

Calderaro

Piloto

et al. 2019

Ther Adv Respir Dis

View full text Add to dashboard Cite

Most physicians understand venous thromboembolism (VTE) to be an acute and time-limited disease. However, pathophysiological and epidemiological data suggest that in most patients VTE recurrence risk is not resolved after the first 6 months of anticoagulation. Recurrence rates are high and potentially life-threatening. In these cases, it would make sense to prolong anticoagulation for an undetermined length of time. However, what about the bleeding rates, induced by prolonged anticoagulation? Would they not outweigh the benefit of reducing the VTE recurrent risk? How long should anticoagulation be continued, and should all patients suffering from VTE be provided with extended anticoagulation? This review will address the most recent data concerning extended anticoagulation in VTE secondary prophylaxis. The reviews of this paper are available via the supplementary material section.

show abstract